7 results about "Depsipeptide" patented technology

An external or topical formulation for treatment or prevention of infections involving body surfaces using a depsipeptide antibiotic drug such as lotilibcin having improved efficacy and safety is provided. The antibacterial effect of lotilibcin tested in infectious models is substantially enhanced by addition of boric acid in a low concentration of an additive level which does not produce any pharmacological activity by itself, thereby offering a formulation for external preparations having improved safety due to a decrease in dose, dosing period, and dosing frequency.

The invention relates to the use of kahalalide-type depsipeptide compounds of formulae I and / or II, obtained from the green alga Pedobesia sp., for controlling a broad spectrum of fungal plant pathogens. The invention also encompasses fungicidal compositions comprising said compounds with a phytologically acceptable carrier, a process for their preparation from Pedobesia biomass, and their use for the preparation of a medicament for treating mycosis such as that caused by Candida albicans or Trichophyton rubrum.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a series of 15-membered ring depsipeptide compounds which are produced by feeding chemical precursors in the fermentation process of streptomyces S.conglobatusATCC 31005, have neoantimycin mother nucleus structures and are synthesized based on precursor feeding, a preparation method of the 15-membered ring depsipeptide compounds and application of the 15-membered ring depsipeptide compounds in anti-tumor drugs. The compound is a 15-membered ring depsipeptide compound synthesized on the basis of precursor feeding, the C-2 site of the compound is connected with a carbonyl group or a hydroxyl group, the C-4 site and the C-9 site are substituted by aliphatic chains with different lengths, and the C-6 site of the compound is connected with a benzoic acid group containing F atoms or hydroxyl groups. The compounds have obvious tumor cell proliferation inhibition activity on colorectal cancer cells and lung cancer cells, the inhibition activity is equivalent to that of a control drug oxaliplatin, and the compounds have weak toxicity on non-cancer cell strains. A novel lead compound is provided for research and development of novel antitumor drugs, and the compound is expected to be developed into a tumor inhibitor.

An embodiment relates to a depsipeptide-based building block for inhibiting protein-protein interactions, a nanostructure including the same, and a use thereof, wherein the depsipeptide-based building block may remain in the body and cells for a long time when administered in vivo and be delivered to a target tissue with high efficiency, and a peptide for inhibiting protein-protein interactions may be gradually released over a long time to obtain a high effect.